Nitrosative Stress, Uric Acid, and Peripheral Nerve Function in Early Type 1 Diabetes
- Robert D. Hoeldtke1,
- Kimberly D. Bryner1,
- Daniel R. McNeill1,
- Gerald R. Hobbs2,
- Jack E. Riggs3,
- Sarah S. Warehime1,
- Ian Christie4,
- Gary Ganser4 and
- Knox Van Dyke5
- 1Department of Medicine, West Virginia University (WVU), Morgantown, West Virginia
- 2Department of Community Medicine and Statistics, WVU, Morgantown, West Virginia
- 3Department of Neurology, WVU, Morgantown, West Virginia
- 4Department of Mathematics, WVU, Morgantown, West Virginia
- 5Department of Biochemistry and Molecular Pharmacology, WVU, Morgantown, West Virginia
Abstract
The present study was performed to determine whether nitric oxide overproduction is associated with deterioration in peripheral nerve function in type 1 diabetes. We measured peripheral nerve function and biochemical indicators of nitrosative stress annually for 3 years in 37 patients with type 1 diabetes. Plasma nitrite and nitrate (collectively NOx) were 34.0 ± 4.9 μmol/l in the control subjects and 52.4 ± 5.1, 50.0 ± 5.1, and 49.0 ± 5.2 in the diabetic patients at the first, second, and third evaluations, respectively (P < 0.01). Nitrotyrosine (NTY) was 13.3 ± 2.0 μmol/l in the control subjects and 26.8 ± 4.4, 26.1 ± 4.3, and 32.7 ± 4.3 in the diabetic patients (P < 0.01). Uric acid was suppressed by 20% in the diabetic patients (P < 0.001). Composite motor nerve conduction velocity for the median, ulnar, and peroneal nerves was decreased in patients with high versus low NTY (mean Z score −0.522 ± 0.25 versus 0.273 ± 0.22; P < 0.025). Patients with high NOx had decreased sweating, and those with suppressed uric acid had decreased autonomic function. In conclusion, nitrosative stress in early diabetes is associated with suppressed uric acid and deterioration in peripheral nerve function.
Footnotes
-
Address correspondence and reprint requests to Robert D. Hoeldtke, West Virginia University School of Medicine, Department of Medicine, One Medical Center Drive, PO Box 9159, Morgantown, WV 26506-9159.
Received for publication 3 April 2002 and accepted in revised form 28 May 2002.
8-iso-PGF2α, 8-isoprostaglandin F2α; ELISA, enzyme-linked immunosorbent assay; eNOS, endothelial nitric oxide synthase; HPLC, high-performance liquid chromatography; iNOS, inducible nitric oxide synthase; NTY, nitrotyrosine; TY, tyrosine; VMA, vanillylmandelic acid.
- DIABETES











